CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine's Approval for Head & Neck Cancer

Stock Information for Cel-Sci Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cel-Sci Corporation

CEL-SCI Announces Closing of Public Offering
CEL-SCI Announces Pricing of Public Offering
CEL-SCI Announces Proposed Public Offering
CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
CEL-SCI Announces Combination of Common Stock
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia-Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.